Nanhua Bio Medicine Co Ltd (SHE:000504) — Market Cap & Net Worth
Market Cap & Net Worth: Nanhua Bio Medicine Co Ltd (000504)
Nanhua Bio Medicine Co Ltd (SHE:000504) has a market capitalization of $380.55 Million (CN¥2.60 Billion) as of June 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #13813 globally and #4136 in its home market, demonstrating a -4.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanhua Bio Medicine Co Ltd's stock price CN¥7.88 by its total outstanding shares 330023098 (330.02 Million). Review 000504 current and long-term liabilities to assess the company's total debt and financial obligations.
Nanhua Bio Medicine Co Ltd Market Cap History: 2015 to 2026
Nanhua Bio Medicine Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.45 Billion to $380.55 Million (-7.15% CAGR).
Nanhua Bio Medicine Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanhua Bio Medicine Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.04x
Nanhua Bio Medicine Co Ltd's market cap is 1.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
14.99x
Nanhua Bio Medicine Co Ltd's market cap is 14.99 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $800.21 Million | $67.25 Million | $21.76 Million | 11.90x | 36.78x |
| 2017 | $1.13 Billion | $67.39 Million | -$37.12 Million | 16.84x | N/A |
| 2018 | $602.21 Million | $95.38 Million | -$35.19 Million | 6.31x | N/A |
| 2019 | $390.21 Million | $134.16 Million | $18.81 Million | 2.91x | 20.75x |
| 2020 | $591.10 Million | $175.56 Million | $8.15 Million | 3.37x | 72.49x |
| 2021 | $898.25 Million | $156.62 Million | -$19.13 Million | 5.74x | N/A |
| 2022 | $562.13 Million | $200.35 Million | -$12.46 Million | 2.81x | N/A |
| 2023 | $560.20 Million | $136.79 Million | -$28.17 Million | 4.10x | N/A |
| 2024 | $403.24 Million | $134.45 Million | -$19.85 Million | 3.00x | N/A |
| 2025 | $432.22 Million | $415.94 Million | $28.83 Million | 1.04x | 14.99x |
Competitor Companies of 000504 by Market Capitalization
Companies near Nanhua Bio Medicine Co Ltd in the global market cap rankings as of June 18, 2026.
Key companies related to Nanhua Bio Medicine Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Nanhua Bio Medicine Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Nanhua Bio Medicine Co Ltd's market cap moved from $1.45 Billion to $ 380.55 Million, with a yearly change of -7.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥380.55 Million | -11.96% |
| 2025 | CN¥432.22 Million | +7.19% |
| 2024 | CN¥403.24 Million | -28.02% |
| 2023 | CN¥560.20 Million | -0.34% |
| 2022 | CN¥562.13 Million | -37.42% |
| 2021 | CN¥898.25 Million | +51.96% |
| 2020 | CN¥591.10 Million | +51.49% |
| 2019 | CN¥390.21 Million | -35.20% |
| 2018 | CN¥602.21 Million | -46.94% |
| 2017 | CN¥1.13 Billion | +41.82% |
| 2016 | CN¥800.21 Million | -44.73% |
| 2015 | CN¥1.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Nanhua Bio Medicine Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $380.55 Million USD |
| MoneyControl | $380.55 Million USD |
| MarketWatch | $380.55 Million USD |
| marketcap.company | $380.55 Million USD |
| Reuters | $380.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanhua Bio Medicine Co Ltd
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment engages in the provision of stem cell, immune cell storage and technical services, and medical device trade. The Energy Saving and Environmental Protection segment is involved in the external energy management … Read more